Junhao JIANG

Dr. Junhao JIANG


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 August 2020 in BMC Chemistry
Verified
Journal Article
Open access
PDF file
SWShuai Wang
Shuai Wang
JJJunhao JIANG
Junhao JIANG
RLRuo-Yu Li
Ruo-Yu Li
Ping DengPing Deng
Ping Deng
To improve the reliability of virtual screening for transforming growth factor-beta type 1 receptor (TβR1) inhibitors, 2 docking methods and 11 scoring functions in Discovery Studio software were evaluated and validated in this study. LibDock and CDOCKER protocols were performed on a test set of 24 TβR1 protein–ligand complexes. Based on the root-mean-square deviation (RMSD) values (in Å) between the docking poses and co-crystal conformations, the CDOCKER protocol can be efficiently applied to obtain more accurate dockings in medium-size virtual screening experiments of TβR1, with a successful docking rate of 95%. A dataset including 281 known active and 8677 inactive ligands was used to determine the best scoring function. The receiver operating characteristic (ROC) curves were used to compare the performance of scoring functions in attributing best scores to active than inactive ligands. The results show that Ludi 1, PMF, Ludi 2, Ludi 3, PMF04, PLP1, PLP2, LigScore2, Jain and LigScore1 are better scoring functions than the random distribution model, with AUC of 0.864, 0.856, 0.842, 0.812, 0.776, 0.774, 0.769, 0.762, 0.697 and 0.660, respectively. Based on the pairwise comparison of ROC curves, Ludi 1 and PMF were chosen as the best scoring functions for virtual screening of TβR1 inhibitors. Further enrichment factors (EF) analysis also supports PMF and Ludi 1 as the top two scoring functions.

1 August 2019 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
YYYu Yu
Yu Yu
DRDongzhi Ran
Dongzhi Ran
JJJunhao JIANG
Junhao JIANG
TPTao Pan
Tao Pan
YDYanrong Dan
Yanrong Dan
ZGZongjie Gan
Zongjie Gan

Verified
Journal Article
Open access
PDF file
JJJunhao JIANG
Junhao JIANG
Ping DengPing Deng
Ping Deng
The transforming growth factor-beta (TGF-β) plays an important role in pathological fibrosis and cancer transformation. Therefore, the inhibition of the TGF-β signaling pathway has therapeutic potential in the treatment of cancer. In this study, the binding modes between 47 molecules with a pyrrolotriazine-like backbone structure and transforming growth factor-beta type 1 receptor (TβR1) were simulated by molecular docking using Discovery Studio software, and their structure–activity relationships were analyzed. On the basis of the analysis of the binding modes of ligands in the active site and the structure–activity relationships, 29,254 new compounds were designed for virtual screening. According to the aforementioned analyses and Lipinski’s rule of five, five new compounds (CQMU1901–1905) with potential activity were screened through molecular docking. Among them, CQMU1905 is an attractive molecule composed of 5-fluorouracil (5-FU), 6-mercaptopurine (6-MP), and 5-azacytosine. Interestingly, 5-FU, 6-MP, and 5-azacytidine are often used as anti-metabolic agents in cancer treatment. Compared with existing compounds, CQMU1901–1905 can interact with target proteins more effectively and have good potential for modification, making them worthy of further study.

2 April 2020 in Xenobiotica
Verified
Journal Article
Closed access
HHHui He
Hui He
YZYuandong Zhang
Yuandong Zhang
DZDezhang Zhao
Dezhang Zhao
JJJunhao JIANG
Junhao JIANG
BXbaogang xie
baogang xie
CYChao Yu
Chao Yu
Osthol, a pharmacologically active ingredient in various traditional Chinese medicines, is predominantly metabolized by CYP2C9. It may be co-administered with other drugs which are metabolized by C...

1 October 2012 in American Journal of Pharmaceutical Education
Verified
Journal Article
Closed access
JJJunhao JIANG
Junhao JIANG
YLYan Liu
Yan Liu
Ping DengPing Deng
Ping Deng
QLQingeng Li
Qingeng Li
This paper describes the status of the bachelor’s degree in clinical pharmacy education in China, with particular focus on educational institutions, programs, and curricula. The authors conducted a systematic literature review of clinical pharmacy education articles published from 2006 to 2011. To ensure the completeness of the investigation, an e-mail was sent or telephone call made directly to the colleges whose curriculum information could not be obtained by the above methodology. Twenty-three colleges offered a program in clinical pharmacy education in 2011. The colleges award either a bachelor of science or a bachelor of medicine degree with programs ranging from 4 to 5 years in duration. The 5-year BS degree program was most popular. Although the number of clinical pharmacy programs in China has steadily increased, more graduates and standardization of curricula are needed to meet the country’s steadily expanding need for quality health care.

31 October 2018 in Molecules
Verified
Journal Article
Open access
PDF file
JJJunhao JIANG
Junhao JIANG
HZHui Zhou
Hui Zhou
QJQihua Jiang
Qihua Jiang
LSLili Sun
Lili Sun
Ping DengPing Deng
Ping Deng
As new drugs for the treatment of malignant tumors, transforming growth factor-beta receptor 1 (TGFβR1) antagonists have attracted wide attention. Based on the crystal structure of TGFβR1-BMS22 complex, the pharmacophore model A02 with two hydrogen bond acceptors (HBAs) and four hydrophobic (HYD) properties was constructed. From the common features of active ligands reported in the literature, pharmacophore model B10 was also generated, which has two aromatic ring centers (RAs) and two HYD properties. The two models have high sensitivity and specificity to the training set, and they are highly consistent in spatial structure. Combining the two pharmacophore models, two novel skeleton structures with potential activity were selected by virtual screening from the DruglikeDiverse, MiniMaybridge, and ZINC Drug-Like databases. Four compounds (YXY01–YXY04) with potential anti-TGFβR1 activity were designed based on the new skeleton structures. In combination with Lipinski’s rules; absorption, distribution, metabolism, excretion, and toxicity (ADMET); and, toxicological properties predicted in the study, YXY01-03 with the novel skeleton, good drug-like properties, and potential activity were finally discovered and may have higher safety relative to BMS22, which may be valuable for further research.